-
25-Hydroxycholesterol–Lysosomal AMPK Axis Reprograms Tumor M
2026-04-21
Xiao et al. reveal that 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages triggers lysosomal AMPKα activation via a GPR155-mTORC1 mechanism, directly phosphorylating STAT6 to drive immunosuppressive phenotypes. This work positions CH25H-driven metabolic reprogramming as a novel immunometabolic checkpoint, offering translational targets for re-educating macrophages and enhancing anti-tumor immunity.
-
FGF4-FGFR1 Signaling Preserves Podocyte Function in Diabetic
2026-04-20
This study uncovers a critical, previously underappreciated role for podocyte-secreted FGF4 in protecting glomerular structure and function during diabetic kidney disease (DKD) progression. By delineating the FGF4-FGFR1-AMPK-FOXO1 signaling axis, the research provides mechanistic insight and highlights FGF4 as a promising therapeutic target to ameliorate DKD.
-
Perospirone (SM-9018 Freebase): Mechanism, Evidence & Resear
2026-04-20
Perospirone (SM-9018 free base) is a high-affinity atypical antipsychotic with dual serotonin-dopamine receptor modulation and Kv1.5 channel inhibition. Its well-characterized pharmacology makes it a robust tool for schizophrenia and cardiovascular research. This article provides protocol parameters, mechanistic evidence, and integration guidance.
-
Lisinopril dihydrate (SKU B3290): Reliable ACE Inhibitor for
2026-04-19
This scenario-driven article guides biomedical researchers through persistent laboratory challenges in cell-based ACE inhibition, with a focus on Lisinopril dihydrate (SKU B3290). Explore protocol-critical issues—solubility, purity, and assay compatibility—backed by literature and product validation to ensure reproducible, high-confidence data in hypertension, heart failure, and nephropathy models.
-
CLCC1 Identified as Host Factor for Herpesvirus Nuclear Egre
2026-04-18
A new study uncovers CLCC1 as a key host protein required for the membrane fusion step of herpesvirus nuclear egress, using a genome-wide CRISPR screen. This mechanistic insight reveals an ancient, conserved pathway in herpesvirus biology and informs the development of targeted antivirals and research assays.
-
Nystatin (Fungicidin): Mechanistic Power in Translational My
2026-04-17
This article explores the strategic integration of Nystatin (Fungicidin) from APExBIO into translational antifungal research. It delves into the mechanistic underpinnings of its action, highlights evidence-backed protocol parameters, and situates its use within the current landscape of antifungal resistance and clinical translation. The piece bridges molecular insight to actionable guidance, differentiating itself by addressing workflow design and cross-species innovation, informed by both recent literature and comparative analyses.
-
Topotecan (SKF104864): New Frontiers in Apoptosis and Pediat
2026-04-16
Explore how Topotecan (SKF104864) advances apoptosis induction and antitumor research in glioma and pediatric solid tumor models. This article provides original insights on protocol design, translational relevance, and practical limitations—distinct from standard mechanistic reviews.
-
Cardiogreen (Indocyanine Green): Applied Workflows in Diagno
2026-04-15
Cardiogreen (Indocyanine Green) from APExBIO is redefining experimental precision—bridging gold-standard vascular diagnostics with next-generation photodynamic therapies. This article delivers actionable protocols, troubleshooting insights, and a translational look at how the latest research unlocks new possibilities for imaging and apoptosis induction.
-
L-NAME Hydrochloride: Precision NOS Inhibition in Vascular R
2026-04-14
L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) is the gold-standard NOS inhibitor for dissecting nitric oxide’s role in vascular tone, apoptosis, and inflammation signaling. This guide details experimental workflows, troubleshooting, and the translational power of APExBIO’s product, supported by benchmark studies and peer-reviewed breakthroughs.
-
Zosuquidar (LY335979): Workflow Innovations in MDR Reversal
2026-04-13
Zosuquidar (LY335979) 3HCl elevates multidrug resistance (MDR) research by precisely and selectively inhibiting P-glycoprotein efflux activity. This guide details robust experimental protocols, troubleshooting strategies, and key insights for acute myeloid leukemia drug sensitization and non-Hodgkin's lymphoma chemotherapy enhancement.
-
S Tag Peptide: Protocol Guidance for Fusion Tag Applications
2026-04-13
S Tag Peptide (SKU A6007) addresses solubility and detection challenges in recombinant protein workflows by providing a highly soluble, reliable fusion tag. It is best suited for affinity purification and anti-S-Tag antibody-based detection, but is not recommended where ethanol solubility or long-term solution storage is required. Its use should be avoided outside the context of protein engineering and molecular biology, as broader applicability is not supported.
-
Dynasore (A1605): Technical Guidance for Dynamin GTPase Inhi
2026-04-12
Dynasore is a non-competitive dynamin GTPase inhibitor used to block dynamin-mediated endocytosis and vesicle trafficking in cellular models. It is best suited for experiments requiring reversible and dose-dependent inhibition of endocytic pathways, but is not appropriate for studies demanding persistent inhibition or for use in aqueous-only solution systems.
-
Single-Dose Gepotidacin in Urogenital Gonorrhea: Phase 2 Res
2026-04-12
This phase 2 study evaluated gepotidacin, a novel bacterial topoisomerase inhibitor, for single-dose oral treatment of uncomplicated urogenital gonorrhea. The results demonstrated ≥95% efficacy in eradicating Neisseria gonorrhoeae, with important implications for antibiotic resistance management.
-
Biotin-HPDP in Thiol-Specific Protein Labeling: Workflows &
2026-04-11
Biotin-HPDP enables highly selective, reversible labeling of protein thiols—empowering advanced detection of S-nitrosylated proteins and affinity purification workflows. Learn how recent research and protocol innovations translate to more robust, controllable, and insightful biotinylation experiments.
-
Losartan in Cardiovascular Physiology Study: Applied Workflo
2026-04-11
Leverage Losartan’s selective angiotensin II receptor antagonism for advanced hypertension and vascular biology research. This guide details optimized experimental workflows, protocol enhancements, and troubleshooting strategies—anchored by recent findings on podocyte protection and vascular repair.